Ambrisentan

Generic Name
Ambrisentan
Brand Names
Letairis, Volibris, Ambrisentan Mylan
Drug Type
Small Molecule
Chemical Formula
C22H22N2O4
CAS Number
177036-94-1
Unique Ingredient Identifier
HW6NV07QEC
Background

Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with ...

Indication

用于治疗肺动脉高血压(PAH)。

Associated Conditions
Pulmonary arterial hypertension WHO functional class I
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

First Posted Date
2009-02-10
Last Posted Date
2020-05-19
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
4
Registration Number
NCT00840463
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Study of Ambrisentan in Participants With Pulmonary Hypertension

Phase 3
Completed
Conditions
Pulmonary Hypertension
Interventions
Drug: Ambrisentan
First Posted Date
2008-10-22
Last Posted Date
2020-09-30
Lead Sponsor
Gilead Sciences
Target Recruit Count
140
Registration Number
NCT00777920
Locations
🇺🇸

Atlanta Institute for Medical Research, Inc., Atlanta, Georgia, United States

🇺🇸

Newark Beth Israel Medical Center, Newark, New Jersey, United States

🇺🇸

University of Pittsburgh Medical Center Presbyterian, Pittsburgh, Pennsylvania, United States

and more 43 locations

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

Phase 3
Terminated
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Placebo
Drug: Ambrisentan
First Posted Date
2008-10-08
Last Posted Date
2014-04-08
Lead Sponsor
Gilead Sciences
Target Recruit Count
494
Registration Number
NCT00768300
Locations
🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 24 locations

A Study to Evaluate the Efficacy of an Oral Medication in the Treatment and Prevention of Digital Ulcers in Patients With Systemic Sclerosis (Scleroderma).

Not Applicable
Completed
Conditions
Scleroderma, Systemic
n Ulcer
Interventions
Drug: Ambrisentan
First Posted Date
2008-07-30
Last Posted Date
2017-03-31
Lead Sponsor
Stanford University
Target Recruit Count
20
Registration Number
NCT00725361
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

An Observational Study For Ambrisentan

Completed
Conditions
Hypertension, Pulmonary
Interventions
Drug: ambrisentan
First Posted Date
2008-05-16
Last Posted Date
2017-03-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
800
Registration Number
NCT00679224
Locations
🇬🇧

GSK Investigational Site, Sheffield, United Kingdom

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

First Posted Date
2008-02-18
Last Posted Date
2012-07-30
Lead Sponsor
Gilead Sciences
Target Recruit Count
38
Registration Number
NCT00617305
Locations
🇺🇸

Scott & White Memorial Hospital, Temple, Texas, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

and more 27 locations

A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: ambrisentan
First Posted Date
2007-12-21
Last Posted Date
2013-01-15
Lead Sponsor
Gilead Sciences
Target Recruit Count
383
Registration Number
NCT00578786
Locations
🇦🇷

Sanatorio Otamendi, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

🇦🇷

Hospital Britanico-Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

🇦🇷

Instituto del Corazon Denton A. Cooley, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

and more 19 locations

Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension

Phase 2
Completed
Conditions
Pulmonary Hypertension
First Posted Date
2007-01-18
Last Posted Date
2013-06-17
Lead Sponsor
Gilead Sciences
Target Recruit Count
36
Registration Number
NCT00423592

Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
First Posted Date
2007-01-18
Last Posted Date
2009-04-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
186
Registration Number
NCT00423748

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Phase 3
Completed
Conditions
Pulmonary Arterial Hypertension
First Posted Date
2007-01-18
Last Posted Date
2009-04-16
Lead Sponsor
Gilead Sciences
Target Recruit Count
186
Registration Number
NCT00423202
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy